//fpnotebook.com/
Intraocular Prostaglandin
Aka: Intraocular Prostaglandin, Latanoprost, Xalatan, Bimatoprost, Lumigan, Travoprost, Travatan, Unoprostone, Rescula, Tafluprost, Zioptan, Vyzulta- Indication
- First line agent for Open Angle Glaucoma
- Mechanism
- Prostaglandin analogs that increase aqueous outflow
- Agents
- Latanoprost (Xalatan) 0.005% one drop daily
- Bimatoprost (Lumigan) 0.03% one drop daily
- Travoprost (Travatan) 0.004% one drop daily
- Unoprostone (Rescula) 0.15% one drop daily
- Tafluprost (Zioptan) 0.0015% one drop daily
- Latanoprostene bunod (Vyzulta)
- Breaks down to Latanoprost and nitric oxide, but with no significant benefit over Latanoprost alone
- Released in 2018, costing 10x the cost of Latanoprost alone (which is $12 per bottle)
- (2018) Presc Lett 25(5): 28
- Efficacy: Latanoprost
- Highly effective, low side effect agent
- Currently most prescribed Glaucoma agent worldwide
- References
- Adverse Effects
Medication Costs | ||
---|---|---|
latanoprost (on 5/17/2017 at Medicaid.Gov Pharmacy Drug pricing) | ||
LATANOPROST 0.005% EYE DROPS | Generic | $2.10 per ml |
xalatan (on 6/1/2017 at Medicaid.Gov Pharmacy Drug pricing) | ||
XALATAN 0.005% EYE DROPS | Generic | $2.10 per ml |
bimatoprost (on 3/22/2017 at Medicaid.Gov Pharmacy Drug pricing) | ||
BIMATOPROST 0.03% EYE DROPS | Generic | $34.15 per ml |
BIMATOPROST 0.03% EYELASH SOLN | Generic | $28.42 per ml |
lumigan (on 2/22/2017 at Medicaid.Gov Pharmacy Drug pricing) | ||
LUMIGAN 0.01% EYE DROPS | $63.23 per ml | |
travoprost (on 8/17/2016 at Medicaid.Gov Pharmacy Drug pricing) | ||
TRAVOPROST 0.004% EYE DROP | Generic | $30.21 per ml |
travatan (on 2/22/2017 at Medicaid.Gov Pharmacy Drug pricing) | ||
TRAVATAN Z 0.004% EYE DROP | $60.10 per ml | |
zioptan (on 5/17/2017 at Medicaid.Gov Pharmacy Drug pricing) | ||
ZIOPTAN 0.0015% EYE DROPS | $5.64 each | |
FPNotebook does not benefit financially from showing this medication data or their pharmacy links. This information is provided only to help medical providers and their patients see relative costs. Insurance plans negotiate lower medication prices with suppliers. Prices shown here are out of pocket, non-negotiated rates. See Needy Meds for financial assistance information. |
latanoprost (C0090306) |
|
---|---|
Definition (NCI) | A prostaglandin F2alpha analogue and a prostanoid selective FP receptor agonist with an ocular hypertensive effect. Latanoprost increases uveoscleral outflow and thereby reduces intraocular pressure. |
Concepts | Pharmacologic Substance (T121) , Organic Chemical (T109) |
MSH | C072042 |
SnomedCT | 330728002, 108838001, 386926002 |
English | latanoprost, Latanoprost [eye], latanoprost (ophthalmic) (medication), latanoprost (ophthalmic), latanoprost ophthalmic, latanoprost [Chemical/Ingredient], Isopropyl (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((3R)-3-hydroxy-5-phenylpentyl)cyclopentyl)-5-heptenoate, LATANOPROST, Latanoprost Ophthalmic, Latanoprost [eye] (product), Latanoprost, Latanoprost (product), Latanoprost (substance), Latanoprost [eye] (substance) |
Spanish | latanoprost (ocular) (producto), latanoprost (ocular), latanoprost (producto), latanoprost (sustancia), latanoprost |
Sources |
Derived from the NIH UMLS (Unified Medical Language System) |
Xalatan (C0593887) |
|
---|---|
Concepts | Pharmacologic Substance (T121) , Organic Chemical (T109) |
MSH | C072042 |
LNC | LA14718-3 |
English | Pfizer brand of latanoprost, xalatan, Xalatan®, Xalatan |
Sources |
Derived from the NIH UMLS (Unified Medical Language System) |
UNOPROSTONE (C0772319) |
|
---|---|
Concepts | Pharmacologic Substance (T121) , Hormone (T125) , Eicosanoid (T111) |
English | unoprostone, UNOPROSTONE, Unoprostone |
Sources |
Derived from the NIH UMLS (Unified Medical Language System) |
travoprost (C0937916) |
|
---|---|
Definition (NCI) | A synthetic lipophilic isopropyl ester prodrug of the active compound travoprost free acid, a prostaglandin F2alpha analog with anti-glaucoma property. Upon administration, travoprost is hydrolysed to a free acid by corneal esterases, and then selectively stimulating the prostaglandin F (FP prostanoid) receptor, thereby increasing the uveoscleral outflow which leads to a reduction in intra-ocular pressure. |
Concepts | Pharmacologic Substance (T121) , Organic Chemical (T109) |
MSH | C438103 |
SnomedCT | 391664000, 129493000 |
English | TRAVOPROST @ @ UNIDENTIFIED, TRAVOPROST UNIDENTIFIED, 5-Heptenoic Acid, 7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((1E,3R)-3-hydroxy-4-(3-(trifluoromethyl)phenoxy)-1-butenyl)cyclopentyl)-, 1-methylethyl Ester,(5Z)-, travoprost (ophthalmic) (medication), travoprost (ophthalmic), travoprost [Chemical/Ingredient], TRAVOPROST, travoprost, travoprost ophthalmic, Travoprost (product), Travoprost (substance), Travoprost |
Spanish | travoprost (producto), travoprost (sustancia), travoprost |
Sources |
Derived from the NIH UMLS (Unified Medical Language System) |
bimatoprost (C0937917) |
|
---|---|
Definition (NCI_NCI-GLOSS) | A drug used under the name Latisse to increase the length, thickness, and darkness of eyelashes. It is being studied as a way to increase the growth of eyelashes and eyebrows in patients given chemotherapy for cancer. Bimatoprost is also used under the name Lumigan to treat glaucoma (a build-up of fluid in the eye). It lowers pressure in the eye by increasing the flow of natural eye fluids out of the eye. It is a type of prostaglandin analog. |
Definition (NCI) | A synthetic prostamide and structural prostaglandin analogue with ocular hypotensive activity. Bimatoprost mimics the effects of the endogenous prostamides and reduces intraocular pressure by increasing outflow of aqueous humor through both the pressure-sensitive outflow pathway (the trabecular meshwork), and the pressure-insensitive outflow pathway (the uveoscleral routes). It is not clear whether bimatoprost lowers intraocular pressure by stimulating F-Prostanoid receptors or by acting on specific prostamide receptors. |
Concepts | Eicosanoid (T111) , Pharmacologic Substance (T121) |
MSH | C420823 |
SnomedCT | 129492005, 395300006 |
English | BIMATOPROST @ @ UNIDENTIFIED, BIMATOPROST UNIDENTIFIED, 5-Heptenamide, 7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((1E,3S)-3-hydroxy-5-phenyl-1-pentenyl)cyclopentyl)-N-ethyl-,(5Z)-, 5-Heptenamide, 7-(3,5-dihydroxy-2-(3-hydrdoxy-5-phenyl-1-pentenyl)cyclopentyl)-N-ethyl-, (1R-(1alpha(Z),2beta(1E,3S*),3alpha,5alpha))-, bimatoprost (medication), bimatoprost [Chemical/Ingredient], bimatoprost, Bimatoprost, Bimatoprost (product), Bimatoprost (substance), BIMATOPROST |
Spanish | bimatoprost (producto), bimatoprost (sustancia), bimatoprost |
Sources |
Derived from the NIH UMLS (Unified Medical Language System) |
Lumigan (C0939372) |
|
---|---|
Concepts | Eicosanoid (T111) , Pharmacologic Substance (T121) |
MSH | C420823 |
English | Lumigan, lumigan, Pharm-Allergan brand of bimatoprost, Allergan brand of bimatoprost |
Sources |
Derived from the NIH UMLS (Unified Medical Language System) |
Eescula (C0939466) |
|
---|---|
Concepts | Pharmacologic Substance (T121) , Eicosanoid (T111) |
MSH | C072630 |
English | Eescula, rescula, Rescula, Ciba Vision brand of isopropyl unoprostone, Novartis brand of isopropyl unoprostone |
Sources |
Derived from the NIH UMLS (Unified Medical Language System) |
Travatan (C0939506) |
|
---|---|
Concepts | Pharmacologic Substance (T121) , Organic Chemical (T109) |
MSH | C438103 |
English | Travatan, travatan, Alcon brand of travoprost |
Sources |
Derived from the NIH UMLS (Unified Medical Language System) |
You are currently viewing the original 'fpnotebook.com\legacy' version of this website. Internet Explorer 8.0 and older will automatically be redirected to this legacy version.
If you are using a modern web browser, you may instead navigate to the newer desktop version of fpnotebook. Another, mobile version is also available which should function on both newer and older web browsers.
Please Contact Me as you run across problems with any of these versions on the website.